vTv Therapeutics (NASDAQ:VTVT) Stock Price Crosses Above Fifty Day Moving Average of $21.35

vTv Therapeutics Inc. (NASDAQ:VTVT) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $21.35 and traded as high as $22.87. vTv Therapeutics shares last traded at $21.20, with a volume of 53,997 shares traded.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut vTv Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, May 13th.

vTv Therapeutics Trading Up 0.9 %

The stock has a fifty day moving average price of $21.35 and a 200-day moving average price of $19.00. The firm has a market capitalization of $63.81 million, a price-to-earnings ratio of -2.40 and a beta of 0.65.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter. The firm had revenue of $1.00 million during the quarter.

Institutional Investors Weigh In On vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. Baker BROS. Advisors LP purchased a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 97,314 shares of the biotechnology company’s stock, valued at approximately $2,290,000. Baker BROS. Advisors LP owned approximately 3.23% of vTv Therapeutics at the end of the most recent reporting period. 17.51% of the stock is owned by institutional investors and hedge funds.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.